Mail slow? View this month’s issue, right online!
Our digital version is easy to share with colleagues. See this month’s issue and digital versions of previous issues too.
Get your products and services in front of thousands of decision-makers. View our print and online advertising options.
A one-on-one interview conducted by our editorial team with industry leaders in our market.
Discover the newest promotions and collaborations within the industry.
Easy-to-digest data for your business.
Shampoos, conditioners, colorants and styling products created by leading industry suppliers.
Creams, serums, facial cleansers and more created by leading suppliers to the skincare industry.
Detergents, fabric softeners and more created by leading suppliers to the fabric care industry.
Eyeshadows, lipsticks, foundations and more created by leading suppliers to the color cosmetics industry.
Bodywashes, and bar and liquid soaps created by leading suppliers to the personal cleanser industry.
Hard surface cleaners, disinfectants and more created by leading suppliers to the home care industry.
Eau de parfums and eau de toilettes, body sprays, mists and more created by leading suppliers to the fragrance industry.
UV lotions and creams, self-tanners and after-sun products created by leading suppliers to the suncare industry.
A detailed look at the leading US players in the global household and personal products industry.
A detailed look at the leading players outside the US in the global household and personal products industry.
Looking for a new raw material or packaging component supplier? Your search starts here.
When you need a new manufacturing partner or private label company, get started here.
Who owns that? To keep track of leading brands and their owners, click here.
An annual publication, Company Profiles features leading industry suppliers with information about markets served, products, technologies and services for beauty, pesonal care and home care.
New products and technologies from some of the brightest minds in the industry.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to the leading experts in the global household and personal products industry.
Comprehensive coverage of key topics selected by sponsors.
Detailed research on novel ingredients and other solutions for the global household and personal care industry.
Company experts explain what works and why.
Exclusive content created by our affiliates and partners for the household and personal care industry.
Exciting news releases from the household and personal care industry.
Our targeted webinars provide relevant market information in an interactive format to audiences around the globe.
Discover exclusive live streams and updates from the hottest events and shows.
Looking for a job in the household and personal care industry, search no further.
Follow these steps to get your article published in print or online
What are you searching for?
Mexican firm flagged by agency works with Markwins.
January 29, 2020
By: Happi Staff
The US FDA has sent a warning letter to Baja Fur S.A. de C.V./Markwins Beauty Brands, Inc. following the inspection of Baja Fur's Tijuana, Mexico facility where Markwins Beauty Brands, Inc. conducts and oversees drug manufacturing operations. The warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). The inspection was conducted from July 8 to 12, 2019, according to the agency. During its inspection, FDA investigators observed specific violations including failture to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). According to FDA, the facility did not adequately investigate the out-of-specification (OOS) microbiological contamination that caused it to reject select batches of its OTC drug product, including results as high as (b)(4) CFU/g. According to FDA, while the company documented these OOS results in an annual product review, it failed to conduct an adequate investigation to prevent recurrence or microbial contamination in the drug products it manufactured for the US market. FDA also said that the firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)). Additionally, FDA said the firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)). According to FDA, failure to correct these violations may also result in the FDA refusing admission of articles manufactured at Baja Fur S.A. de C.V. into the US under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Additional details can be accessed here.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !